SA001 Shank3 Homo1
CEBe033-A-5
General
Cell Line |
|
hPSCreg name | CEBe033-A-5 |
Cite as: | CEBe033-A-5 (RRID:CVCL_C9Z1) |
Alternative name(s) |
SA001 Shank3 Homo1
|
Cell line type | Human embryonic stem cell (hESC) |
Similar lines |
CEBe033-A-2 (SA001 Shank3 hetero1) CEBe033-A-3 (SA001 Shank3 Hetero2) CEBe033-A-4 (SA001 Shank3 Hetero3) CEBe033-A-6 (SA001 Shank3 Homo2) CEBe033-A-7 (SA001 Shank3 Homo3) CEBe033-A (SA001) CEBe033-A-8 (SA001_KO_HGPRT_1) CEBe033-A-9 (SA001_KO_HGPRT_2) CEBe033-A-10 (SA001_WT_HGPRT_1) CEBe033-A-11 (SA001_WT_HGPRT_2) CEBe033-A-1 (GBA1_hESC_GBA#1-/-_10.18.11) |
Last update | 21st April 2023 |
User feedback | |
Provider |
|
Generator | Institut from Stem cell Therapy and Exploration of Monogenic diseases (ISTEM) |
Derivation country | France |
External Databases |
|
BioSamples | SAMEA112927564 |
Cellosaurus | CVCL_C9Z1 |
Wikidata | Q123030889 |
General Information |
|
Publications | |
* Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Subclone of |
Donor Information
General Donor Information |
|
Sex | male |
Phenotype and Disease related information (Donor) |
|
Diseases | No disease was diagnosed.
|
Disease associated phenotypes | no phenotypes |
Karyotyping (Donor) |
|
Has the donor karyotype been analysed? |
Yes
|
Other Genotyping (Donor) |
|
Is there genome-wide genotyping or functional data available? |
No
|
External Databases (Donor) |
|
BioSamples | SAMEA104132810 |
Ethics
Also have a look at the ethics information for the parental line
CEBe033-A
.
Is there an MTA available for the cell line? | Yes |
Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | Yes |
Constraints for use or distribution | Work with human embryonic stem cells requires prior approval by local ethics committees. |
hESC Derivation
The source cell information can be found in the parental cell line
CEBe033-A.
|
Culture Conditions
Surface coating | Vitronectin | ||||||
Feeder cells |
No |
||||||
Passage method | Mechanically | ||||||
CO2 Concentration | 5 % | ||||||
Medium |
Other medium:
Base medium: StemMacs IPS-Brew XF
Main protein source: Serum concentration: % Supplements
|
||||||
Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
||||||
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
||||||
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
SSEA-4 |
Yes |
|
|
|||
NANOG |
Yes |
|
Morphology pictures
Shank3celllines_brightfields.pdf
Brightfields Panel
Differentiation Potency
In vitro spontaneous differentiation
Morphology
Shank3celllines_triligneage.pdf
Spontaneaous Differentiation in three Germ layers
In vitro spontaneous differentiation
Marker | Expressed |
ACTA2 |
Yes |
Morphology
Shank3celllines_triligneage.pdf
Spontaneaous Differentiation in three Germ layers
In vitro spontaneous differentiation
Morphology
Shank3celllines_triligneage.pdf
Spontaneaous Differentiation in three Germ layers
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
Normal Karyotype 46XY
Passage number: 88
Karyotyping method:
Spectral karyotyping
|
Other Genotyping (Cell Line) |
|
Is there genome-wide genotyping or functional data available? |
Yes
SNP typing array
No Mutation |
Genetic Modification
Disease/phenotype related modifications |
|
Login to share your feedback, experiences or results with the research community.